Century Therapeutics, Inc.
IPSC Healthcare Biotechnology
Century Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $109.2 million, up 1,556.8% from fiscal 2024. In the quarter to June 2026, revenue grew 12,667.7%, EPS grew 55.3% and free cash flow grew 26.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow IPSC
Century Therapeutics, Inc. (IPSC) Altman Z-score
Century Therapeutics, Inc.'s Altman Z-score for fiscal 2025 is −3.39, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −3.39 | 0.52 |
| FY2024 | −3.91 | (1.23) |
| FY2023 | −2.68 | (1.97) |
| FY2022 | −0.71 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.45 | — | 0.54 | |
| Retained earnings / total assets | (3.54) | — | −4.96 | |
| EBIT / total assets | (0.08) | — | −0.25 | |
| Market value of equity / total liabilities | 1.33 | — | 0.80 | |
| Sales / total assets | 0.49 | — | 0.49 | |
| Altman Z-score | Distress zone | −3.39 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −6.53 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| EYPT EyePoint, Inc. compare | 8.5× |
| FULC Fulcrum Therapeutics, Inc. compare | 8.2× |
| ABEO Abeona Therapeutics Inc. compare | −2.3× |
| IPSC Century Therapeutics, Inc. | −3.4× |
| PRLD Prelude Therapeutics Incorporated compare | −6.8× |
| PALI Palisade Bio, Inc. compare | −13.4× |
| OCGN Ocugen, Inc. compare | −13.4× |
| NAUT Nautilus Biotechnology, Inc. compare | — |
| CABA Cabaletta Bio, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets